[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350246-105":59,"doc-detail-350246-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","current-evidence-and-emerging-approaches-in-immunotherapy-for-gynecological-cancers","Current evidence and emerging approaches in immunotherapy for gynecological cancers","","Gynecological cancers, including vulvar, cervical, endometrial, and ovarian disease, drive major global morbidity and mortality in women. Conventional chemotherapy, surgery, and radiotherapy show limited success because of adverse effects, resistance, and tumor heterogeneity. This narrative review synthesizes peer-reviewed immunotherapy evidence published up to 2023 from Scopus, PubMed, PubMed Central, and Google Scholar, emphasizing immune checkpoint inhibitors, cytokine therapies, cancer vaccines, and adoptive T cell approaches. It highlights promising responses with agents such as nivolumab and pembrolizumab in defined patient subsets, while addressing immune toxicity, resistance, and patient variability, and outlining future biomarker and combination strategies.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-evidence-and-emerging-approaches-in-immunotherapy-for-gynecological-cancers/350246/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-evidence-and-emerging-approaches-in-immunotherapy-for-gynecological-cancers/350246.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"What major limitations remain despite advances in immunotherapy?","Question",{"text":112,"@type":113},"Key limitations include immune-related side effects, treatment resistance, and heterogeneity among patients, motivating further work on predictive biomarkers and combination therapies.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},350246,1790238334,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":24,"preview_urls":138},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Ashonibare et al. Discover Oncology (2026) 17:705  \n[https://doi.org/10.1007/s12672-026-04785-9](https://doi.org/10.1007/s12672-026-04785-9)  \nDiscover Oncology  \nREVIEW Open Access  \nCurrent evidence and emerging approaches  in immunotherapy for gynecological cancers  \nVictory Jesutoyosi Ashonibare 1,2, Oluwaseun Samuel Hezekiel2,3, Omotola Seunfunmi Kukoyi2,4, Suliat Adenike Hassan2, Olaol uwa Ayoade Afolabi2,5, Tunmise Maryanne Akhigbe2,6 and Roland Eghoghosoa Akhigbe2,3*  \n*Correspondence:  \nRoland Eghoghosoa Akhigbe[reakhigbe@gmail.com](reakhigbe@gmail.com); reakhigbe@ [lautech.edu.ng](lautech.edu.ng)  \n1Cardiovascular Regenerative Medicine & Tissue Engineering 3D Lab, Department of Cardiovascular Surgery and Research Group for Experimental Surgery, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany 2Reproductive Biology and Toxicology Research Laboratory, Oasis of Grace Hospital, Osogbo, Osun State, Nigeria  \n3Department of Physiology, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria 4Functional Microbiome  \nGroup, Uniklinik Aachen (Universitätsklinikum Aachen), Aachen, Germany  \n5Department of Obstetrics and Gynaecology, Bowen University Teaching Hospital, Ogbomoso, Oyo State, Nigeria  \n6Department of Agronomy, Osun State University, Ejigbo campus, Ejigbo, Osun State, Nigeria  \nAbstract  \nGynecological cancers, such as vulvar, cervical, endometrial, and ovarian cancers, are the leading causes of morbidity and mortality among women globally. Conventional management modalities like chemotherapy, surgery, and radiotherapy have achieved limited success due to adverse side effects, resistance development, and tumor heterogeneity. Recognizing the urgent need for innovative therapeutic strategies, this narrative review explores the evolving role of immunotherapy in the management of these cancers. A comprehensive literature search was conducted using Scopus, PubMed, PubMed Central, and Google Scholar databases, focusing on peer-reviewed articles published up to 2023. The selection prioritized studies that evaluated immunotherapeutic approaches, including immune checkpoint inhibitors, cytokine therapies, cancer vaccines, and adoptive T cell therapies in gynecological cancers, with particular attention to clinical trials, preclinical studies, and reviews discussing mechanisms, outcomes, and challenges. Our synthesis reveals that immune checkpoint blockade agents, such as nivol umab and pembrolizumab, demonstrate promising responses in specific patient subsets, notably those with HPVassociated tumors and high mutational burdens. Despite these advances, significant limitations persist, including immune-related side effects, treatment resistance, and patient heterogeneity. Ongoing efforts to identify predictive biomarkers and develop combination therapies aim to overcome these hurdles. In conclusion, immunotherapy holds substantial potential for improving outcomes in gynecological cancers. Nonetheless, further research is needed to elucidate mechanisms of resistance, optimize patient selection, and establish effective treatment protocols. Keywords Cancer, Checkpoint inhibitors, Immunology, Immunoresistance, Immunotolerance, Vaccines  \n1 Introduction  \nGynecological malignancies like vulvar, cervical, endometrial, and ovarian cancers are a global challenge and account for a significant percentage of cancer-related morbidity and mortality among women [255]. Globally, cervical cancer remains the fourth most common cancer among women, with about 210,000 children losing their mothers to it each  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified th","cbCaib1wx8KRFGP2","https://ap.wps.com/l/cbCaib1wx8KRFGP2","pdf",4460281,41,"English","# Abstract\n# 1 Introduction\n## Gynecological cancer burden\n## Limitations of conventional therapies\n## Rationale for immunotherapy","[{\"question\":\"What major limitations remain despite advances in immunotherapy?\",\"answer\":\"Key limitations include immune-related side effects, treatment resistance, and heterogeneity among patients, motivating further work on predictive biomarkers and combination therapies.\"}]","Current evidence and emerging approaches in immunotherapy for gynecological cancers | PDF",1790088023,103,[139,143,147,151,155],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6fd91c97eddb37344f0faed3792353cc.webp",983,1310,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07bd5ef60aba0ae9643604fd07955b29.webp",982,1309,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5579728320f8a7b8d438c05f285c02a.webp",981,1308,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cffb39c865d1efbafbe2caba4fa7f8b.webp",980,1306,{"page_no":24,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52d58c5e13a7f8682e49abbd6bf318c1.webp",979,1305]